As expected, such dual PI3K/mTOR inhibitors have higher efficacy than rapalogs in aggressive NH B-cell lymphomas in vitro and in vivo (131) but they have raised concerns of dose-limited toxicities that are thought to be linked to their low selectivity toward mTORC1 (132, 133). The gene discussed is PIK3CA; the disease is B-cell non-Hodgkin lymphoma.